According to Jogender Tushir-Singh from the University of Virginia's (UVA) a major problem with immune therapies for ovarian cancer is that the immune cells intended to kill the cancer cells could not infiltrate the solid tumour bed effectively. So he engineered an antibody that he likens to a two-headed arrow. One head of this dual pronged arrow strikes what is known as the death receptor on the cancer cells forcing them to die while the other head strikes a receptor known as FOLR1 a well established marker that suggests a poor prognosis. There are a lot of efforts in terms
